AGEN
Agenus Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Buy
+21/100
Last price
7.53
▼ 1.20 (13.75%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
8.62
Prev close
8.73
Day high
8.49
Day low
7.47
Volume
1.53M
Market cap
$338.26M
P/E (TTM)
2.96
52W range
2.71 – 10.31
Day trading desk
Gap from prior close
-1.26%
Prior close 8.73
VWAP
7.69
-2.04% from price
Relative volume
0.70×
Normal
Session range
17.30%
7.40 – 8.68
Position in range
10%
Near session low
ATR (14D)
0.74
9.80% of price
Prior day high
8.76
PDH
Prior day low
8.11
PDL
Bid / ask spread
—
Quote not published
Session volume
2.96M
Avg 4.20M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-24.27%
-26.2%
1M
-9.10%
-10.3%
3M
+130.46%
+125.9%
6M
+84.48%
+66.3%
YTD
+138.54%
+124.3%
1Y
+80.92%
+64.5%
3Y
-66.86%
-149.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on AGEN open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
2.82M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 10, 26 | ARMEN GARO H. Chief Executive Officer |
STOCK | 4.85K | $16.25K | Direct |
| Jul 1, 26 | HARRISON THOMAS L Director |
STOCK | 8.55K | $30.62K | Direct |
| Jun 26, 26 | ARMEN GARO H. Chief Executive Officer |
STOCK | 5.36K | $16.25K | Direct |
| Jun 12, 26 | ARMEN GARO H. Chief Executive Officer |
STOCK | 4.92K | $16.25K | Direct |
| May 29, 26 | ARMEN GARO H. Chief Executive Officer |
STOCK | 4.64K | $16.25K | Direct |
| May 15, 26 | ARMEN GARO H. Chief Executive Officer |
STOCK | 4.54K | $16.25K | Direct |
| May 1, 26 | ARMEN GARO H. Chief Executive Officer |
STOCK | 4.23K | $16.25K | Direct |
| Apr 17, 26 | ARMEN GARO H. Chief Executive Officer |
STOCK | 3.40K | $16.30K | Direct |
| Apr 2, 26 | ARMEN GARO H. Chief Executive Officer |
STOCK | 4.63K | $15.41K | Direct |
| Apr 1, 26 | HARRISON THOMAS L Director |
STOCK | 9.23K | $30.63K | Direct |
| Mar 20, 26 | ARMEN GARO H. Chief Executive Officer |
STOCK | 3.98K | $14.78K | Direct |
| Mar 6, 26 | ARMEN GARO H. Chief Executive Officer |
STOCK | 4.99K | $14.78K | Direct |
| Feb 20, 26 | ARMEN GARO H. Chief Executive Officer |
STOCK | 4.83K | $14.78K | Direct |
| Feb 6, 26 | ARMEN GARO H. Chief Executive Officer |
STOCK | 5.03K | $14.78K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ARMEN GARO H. |
Chief Executive Officer | 431.36K | Stock Award(Grant) |
BUELL JENNIFER |
Director | 19.74K | Stock Award(Grant) |
HARRISON THOMAS L |
Director | 47.55K | Stock Award(Grant) |
KLASKIN CHRISTINE M |
Officer | 23.48K | Stock Award(Grant) |
O'DAY STEVEN J |
Officer | 57.12K | Stock Award(Grant) |
Fundamentals
Market cap$338.26M
Enterprise value$352.40M
Revenue (TTM)$132.69M
Gross profit$150.75M
EBITDA$40.61M
Net income$91.80M
EPS (TTM)$2.53
Free cash flow$-74.79M
Total cash$18.74M
Total debt$40.71M
Book value / share$-4.67
Shares outstanding45.16M
Float40.23M
Short % of float15.24%
Dividend yield0.00%
Beta (5Y)1.32
Valuation & profitability ratios
Trailing P/E2.96
Forward P/E-68.09
PEG ratio1.44
Price / sales—
Price / book—
EV / revenue2.66
EV / EBITDA8.68
Gross margin113.61%
Operating margin32.72%
Profit margin69.34%
Return on equity—
Return on assets12.53%
Debt / equity—
Current ratio0.34
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $114.20M | $103.46M | $156.31M | $98.02M | +10.4% |
| Operating revenue | $5.61M | $2.48M | $41.74M | $52.74M | +125.7% |
| Cost of revenue | $80.36M | $156.01M | $237.68M | $197.26M | -48.5% |
| Gross profit | $33.84M | -$52.55M | -$81.37M | -$99.23M | +164.4% |
| Selling, general & admin | $54.39M | $71.88M | $78.74M | $81.01M | -24.3% |
| Total operating expense | $54.39M | $71.88M | $78.74M | $81.01M | -24.3% |
| Operating income | -$20.56M | -$124.43M | -$160.10M | -$180.24M | +83.5% |
| Net interest income | -$55.27M | -$117.63M | -$97.92M | -$61.86M | +53.0% |
| Pre-tax income | -$3.08M | -$232.27M | -$257.44M | -$230.66M | +98.7% |
| Net income | $115.00K | -$227.21M | -$245.76M | -$220.07M | +100.1% |
| Net income to common | -$101.00K | -$227.43M | -$245.97M | -$220.29M | +100.0% |
| Basic EPS | 0.00 | -10.59 | -13.75 | -15.64 | +100.0% |
| Diluted EPS | 0.00 | -10.59 | -13.75 | -15.64 | +100.0% |
| EBIT | $52.19M | -$114.64M | -$159.51M | -$168.79M | +145.5% |
| EBITDA | $62.19M | -$101.30M | -$145.92M | -$161.85M | +161.4% |
| Basic shares | 29.73M | 21.47M | 17.89M | 14.09M | +38.5% |
| Diluted shares | 29.73M | 21.47M | 17.89M | 14.09M | +38.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.00M | $40.44M | $76.11M | $178.67M | — | -92.6% |
| Cash & short-term investments | $3.00M | $40.44M | $76.11M | $193.36M | — | -92.6% |
| Accounts receivable | $1.83M | $407.00K | $25.84M | $2.74M | — | +349.9% |
| Total current assets | $133.44M | $45.57M | $112.42M | $213.12M | — | +192.8% |
| Property, plant & equipment | $23.21M | $147.40M | $163.03M | $164.29M | — | -84.3% |
| Goodwill & intangibles | $27.13M | $27.47M | $29.13M | $31.70M | — | -1.2% |
| Total assets | $226.80M | $226.27M | $313.91M | $413.56M | — | +0.2% |
| Total current liabilities | $323.49M | $221.40M | $255.90M | $188.95M | — | +46.1% |
| Current debt | $44.66M | $2.70M | $146.00K | $575.00K | — | +1,555.1% |
| Long-term debt | — | $30.47M | $12.77M | $12.58M | $12.82M | — |
| Total debt | $55.90M | $94.87M | $88.47M | $78.43M | — | -41.1% |
| Total liabilities | $504.66M | $532.70M | $462.30M | $468.46M | — | -5.3% |
| Retained earnings | -$2.18B | -$2.18B | -$1.96B | -$1.71B | — | +0.0% |
| Shareholder equity | -$271.11M | -$326.38M | -$160.33M | -$61.28M | — | +16.9% |
| Working capital | -$190.05M | -$175.83M | -$143.48M | $24.17M | — | -8.1% |
| Net tangible assets | -$298.24M | -$353.85M | -$189.47M | -$92.97M | — | +15.7% |
| Shares issued | 35.32M | 23.63M | 19.72M | 15.28M | — | +49.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$3.08M | -$232.27M | -$257.44M | -$230.66M | +98.7% |
| Depreciation & amortisation | $10.00M | $13.34M | $13.59M | $6.95M | -25.1% |
| Stock-based compensation | $13.77M | $17.39M | $22.87M | $18.34M | -20.8% |
| Change in working capital | $27.33M | $32.60M | $10.76M | $24.08M | -16.2% |
| Operating cash flow | -$77.19M | -$158.31M | -$224.20M | -$175.37M | +51.2% |
| Capital expenditure | -$6.00K | -$576.00K | -$9.95M | -$53.06M | +99.0% |
| Investing cash flow | $1.19M | $27.00K | $3.40M | -$33.61M | +4,322.2% |
| Share buybacks | -$87.00K | $0 | -$5.17M | -$3.79M | — |
| Financing cash flow | $36.59M | $122.84M | $119.87M | $95.83M | -70.2% |
| Free cash flow | -$77.20M | -$158.89M | -$234.16M | -$228.44M | +51.4% |
| End cash position | $4.71M | $44.07M | $79.78M | $181.34M | -89.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $34.52M | $33.74M | $34.20M | $30.23M | $25.69M | — | +2.3% |
| Operating revenue | $6.37M | $4.59M | $3.15M | $1.09M | $860.00K | — | +38.8% |
| Cost of revenue | $14.76M | $11.82M | $7.51M | $24.24M | $26.95M | — | +24.8% |
| Gross profit | $19.76M | $21.91M | $26.69M | $6.00M | -$1.26M | — | -9.8% |
| Selling, general & admin | $8.47M | $6.86M | $12.29M | $10.86M | $15.52M | — | +23.4% |
| Total operating expense | $8.47M | $6.86M | $12.29M | $10.86M | $15.52M | — | +23.4% |
| Operating income | $11.29M | $15.05M | $14.40M | -$4.86M | -$16.78M | — | -25.0% |
| Net interest income | -$15.24M | -$14.67M | -$16.02M | -$13.17M | -$13.29M | — | -3.9% |
| Pre-tax income | -$567.00K | $39.21M | -$10.61M | $63.91M | -$30.01M | — | -101.4% |
| Net income | -$550.00K | $39.23M | -$10.58M | $63.91M | -$27.95M | — | -101.4% |
| Net income to common | -$604.00K | $39.17M | -$10.63M | $63.86M | -$28.01M | — | -101.5% |
| Basic EPS | -0.01 | 1.03 | — | 2.00 | -1.00 | -1.03 | -101.0% |
| Diluted EPS | -0.01 | 1.02 | — | 1.94 | -1.00 | -1.03 | -101.0% |
| EBIT | $14.68M | $53.88M | $5.41M | $77.08M | -$16.72M | — | -72.8% |
| EBITDA | $15.19M | $54.46M | $6.00M | $80.11M | -$13.55M | — | -72.1% |
| Basic shares | 41.34M | 37.94M | — | 31.89M | 28.12M | 24.47M | +9.0% |
| Diluted shares | 41.34M | 38.28M | — | 32.86M | 28.12M | 24.47M | +8.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $18.74M | $35.00M | $3.00M | $3.46M | $9.53M | — | -46.5% |
| Cash & short-term investments | $18.74M | $35.00M | $3.00M | $3.46M | $9.53M | — | -46.5% |
| Accounts receivable | $14.72M | $6.56M | $1.83M | $538.00K | $709.00K | — | +124.4% |
| Total current assets | $78.81M | $95.28M | $133.44M | $133.95M | $13.34M | — | -17.3% |
| Property, plant & equipment | $21.53M | $22.41M | $23.21M | $24.01M | $139.14M | — | -3.9% |
| Goodwill & intangibles | $26.97M | $27.05M | $27.13M | $27.21M | $27.30M | — | -0.3% |
| Total assets | $172.69M | $186.46M | $226.80M | $233.89M | $185.22M | — | -7.4% |
| Total current liabilities | $231.82M | $249.24M | $323.49M | $287.13M | $234.56M | — | -7.0% |
| Current debt | $30.07M | $30.19M | $44.66M | $10.61M | $10.72M | — | -0.4% |
| Long-term debt | — | — | — | $23.60M | $23.15M | $32.85M | — |
| Total debt | $40.71M | $41.07M | $55.90M | $45.77M | $90.53M | — | -0.9% |
| Total liabilities | $378.54M | $414.44M | $504.66M | $514.76M | $521.53M | — | -8.7% |
| Retained earnings | -$2.14B | -$2.14B | -$2.18B | -$2.17B | -$2.24B | — | -0.0% |
| Shareholder equity | -$199.07M | -$221.22M | -$271.11M | -$274.14M | -$354.60M | — | +10.0% |
| Working capital | -$153.01M | -$153.95M | -$190.05M | -$153.18M | -$221.22M | — | +0.6% |
| Net tangible assets | -$226.05M | -$248.27M | -$298.24M | -$301.35M | -$381.90M | — | +9.0% |
| Shares issued | 42.62M | 38.52M | 35.32M | 32.81M | 30.00M | — | +10.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$567.00K | $39.21M | -$10.61M | $63.91M | -$30.01M | — | -101.4% |
| Depreciation & amortisation | $517.00K | $583.00K | $597.00K | $3.03M | $3.17M | — | -11.3% |
| Stock-based compensation | $3.61M | $1.10M | $3.46M | $3.24M | $3.58M | — | +228.6% |
| Change in working capital | -$19.27M | -$23.80M | -$3.81M | $12.52M | $13.71M | — | +19.0% |
| Operating cash flow | -$31.20M | -$35.95M | -$16.62M | -$14.74M | -$20.22M | — | +13.2% |
| Capital expenditure | — | — | — | — | -$1.00K | -$5.00K | — |
| Investing cash flow | $267.00K | $68.95M | $780.00K | $76.00K | $281.00K | — | -99.6% |
| Share buybacks | -$27.00K | -$27.00K | $0 | $0 | -$65.00K | — | 0.0% |
| Financing cash flow | $14.68M | -$993.00K | $15.37M | $6.68M | $10.94M | — | +1,578.8% |
| Free cash flow | -$31.20M | -$35.95M | -$16.62M | -$14.74M | -$20.22M | — | +13.2% |
| End cash position | $20.45M | $36.71M | $4.71M | $5.17M | $13.17M | — | -44.3% |
Options analytics
Put / call volume
0.52
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
1.00
-86.6% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
277
Contracts, this expiry
Put volume
143
Contracts, this expiry
Heaviest call OI
1.00
0 contracts
Heaviest put OI
6.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.04 | -0.01 | -125.0% |
| Mar 2026 | 1.80 | -0.03 | -101.8% |
| Dec 2025 | -1.30 | 0.68 | +152.4% |
| Sep 2025 | 2.20 | -1.16 | -152.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.04 | 1 | $28.23M | -6.5% |
| Next quarter | 0.04 | 1 | $28.77M | -15.9% |
| Current year | 0.50 | 1 | $125.20M | +9.6% |
| Next year | -0.11 | 1 | $115.97M | -7.4% |
Analyst targets & ownership
Mean target$26.33
High target$40.00
Low target$14.00
Implied upside249.71%
Analyst count3
ConsensusSTRONG BUY
Strong buy / Buy0 / 3
Hold0
Sell / Strong sell0 / 0
Held by insiders6.27%
Held by institutions46.38%
Institutions holding154
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
8.76
-14.04% from price
SMA 20
8.09
-7.47% from price
SMA 50
7.80
-3.93% from price
SMA 100
5.77
+30.60% from price
SMA 200
4.64
+61.33% from price
EMA 12
8.46
-10.94% from price
EMA 26
8.15
-7.60% from price
EMA 50
7.51
+0.30% from price
RSI (14)
44.3
Neutral
MACD (12,26,9)
0.31
Hist -0.09
ATR (14)
0.74
9.85% of price
Realised vol 30D
97.8%
Annualised
Bollinger upper
9.98
20, 2σ
Bollinger lower
6.20
20, 2σ
50 / 200 cross
Golden
7.80 vs 4.64
Trend bias
Above 200
+61.33%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.44
More volatile than market
Correlation to SPY
0.16
Largely independent
Realised vol 30D
97.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-40.8%
Peak to trough
Max drawdown 5Y
-98.7%
Peak to trough
ATR 14
0.74
9.85% of price
Beta (reported)
1.32
5Y monthly, from filing
Short interest
Shares short
6.80M
Prior 5.86M
Change vs prior
+16.0%
Shorts adding
% of float
15.24%
Elevated
% of shares out
15.07%
Against total outstanding
Days to cover
6.8
Crowded exit
Float
40.23M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Sep 28, 26 | Rodman & Renshaw | INITIATED | — | Buy |
| Sep 18, 26 | Chardan Capital | INITIATED | — | Buy |
| Aug 11, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 30, 26 | B. Riley Securities | MAINTAINED | Buy | Buy |
| Jul 13, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 10, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 28, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 4, 25 | Baird | MAINTAINED | Neutral | Neutral |
| Jun 4, 25 | HC Wainwright & Co. | UPGRADE | Neutral | Buy |
| May 13, 25 | HC Wainwright & Co. | MAINTAINED | Neutral | Neutral |
| May 13, 25 | Baird | MAINTAINED | Neutral | Neutral |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:20
Split dateApr 12, 2024
SEC filings
Offering Registrations
S-3 · 2026-09-11
Offering Registrations
S-8 · 2026-09-02
Corporate Changes & Voting Matters
8-K · 2026-08-18
Corporate Changes & Voting Matters
8-K · 2026-08-13
Corporate Changes & Voting Matters
8-K · 2026-08-11
Periodic Financial Reports
10-Q · 2026-08-07
Corporate Changes & Voting Matters
8-K · 2026-08-06
Offering Registrations
S-3 · 2026-07-20
Headlines
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Business Wire · 4d ago
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
Business Wire · 5d ago
Agenus Shares Rise After Chardan Initiates Coverage at Buy
MT Newswires · 9d ago
Agenus (AGEN) Stock Fair Value Rises After Trial Updates And Fresh Financing
Simply Wall St. · 17d ago
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Business Wire · 27d ago
Agenus to Participate in Upcoming September Investor Conferences
Business Wire · 37d ago
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
Business Wire · 40d ago
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
Business Wire · 42d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.